Nurix Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nurix Therapeutics, Inc.
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
Already Closing In On Imbruvica With Brukinsa, BeiGene Sets Its Sights On Another Hematology Blockbuster
BeiGene is seeing rapid growth thanks to Brukinsa’s head-to-head superiority in CLL to the leading BTK inhibitor, Imbruvica, and now the company aims to repeat that feat by taking on another blood cancer big-hitter, Venclexta.
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- DeCART Therapeutics
- Nurix, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.